Radius Health, Inc.

Report azionario NasdaqGM:RDUS

Capitalizzazione di mercato: US$480.8m

This company has been acquired

The company may no longer be operating, as it has been acquired. Find out why through their latest events.

Radius Health Gestione

Criteri Gestione verificati 2/4

Informazioni chiave

G. Martin

Amministratore delegato

US$3.5m

Compenso totale

Percentuale dello stipendio del CEO17.17%
Mandato del CEO2.3yrs
Proprietà del CEOn/a
Durata media del managementless than a year
Durata media del Consiglio di amministrazione6.8yrs

Aggiornamenti recenti sulla gestione

Nessun aggiornamento

Recent updates

Seeking Alpha • Mar 14

Radius Recycling's Surge Justifies A Reevaluation

Summary Radius Recycling, Inc. shares surged after agreeing to a $30 per share buyout by Toyota Tsusho, offering a 115% premium over the closing price. Despite operational challenges and declining revenues, the buyout provides a significant 77.8% upside since my “buy” rating in June last year. Toyota Tsusho's acquisition reflects their strategic interest in metals recycling, but they assume all risks amid potential market recovery and volatility. Given the substantial premium and limited future upside, I recommend downgrading RDUS stock to a “hold” to align with broader market performance expectations. Read the full article on Seeking Alpha
Seeking Alpha • Feb 25

Radius Recycling Will Benefit From Steel Tariffs

Summary Radius Recycling's profitability is poised to improve due to rising domestic steel prices driven by tariffs, which will increase scrap steel prices and expand margins. Despite historical underperformance, the company's margins will benefit from higher scrap prices without significant cost increases, making it a speculative buy. Monitoring scrap steel prices before Radius's next earnings report could reveal an undervalued stock if the market hasn't yet recognized this linkage. Investing in Radius should be modest, as its viability heavily relies on the continuation of steel tariffs boosting scrap prices. Read the full article on Seeking Alpha
Seeking Alpha • Jul 16

Radius Recycling Stays In The Scrap Pile

Summary Radius Recycling experienced a significant decline in share price, hitting a 52-week low of $12.72. The company is implementing strategic changes to boost profits, including upgrades to non-ferrous scraping capabilities and cost reduction initiatives. Economic indicators such as durable goods orders, average vehicle age, and Chinese steel export production will impact Radius Recycling's business in the near future. Read the full article on Seeking Alpha
Seeking Alpha • Jun 03

Radius Recycling: An Attractive, But Volatile, Play On A Cleaner Future

Summary Radius Recycling, Inc. is a large recycler of ferrous and nonferrous metal, with operations in metals recycling, auto parts stores, and steel manufacturing. The company's financial performance has been volatile due to fluctuating steel prices, but its stock is trading at low multiples. Despite short-term challenges, the long-term potential of the recycling industry makes Radius Recycling a cheap business worth considering. Read the full article on Seeking Alpha
Seeking Alpha • Aug 11

Radius stock rises as elacestrant gets FDA priority review to treat breast cancer subtype

The U.S. Food and Drug Administration (FDA) granted priority review to Menarini's application seeking approval of elacestrant to treat patients with ER+/HER2- advanced or metastatic breast cancer. The FDA accepted the Italian pharmaceutical and diagnostic company's new drug application (NDA) and is expected to make a decision by Feb. 17, 2023. Under priority review, the FDA's goal is to take action within six months, compared to 10 months under standard review. The NDA was backed by data from a phase 3 trial called EMERALD, which was conducted by Radius Health (NASDAQ:RDUS).  Menarini had obtained global licensing rights for elacestrant from Radius in July 2020. Menarini noted that it had filed for approval of the drug in the EU in July 2022. Elacestrant had received the FDA's fast track designation in 2018. RDUS +5.56% to $10.64 premarket Aug. 11
Seeking Alpha • Feb 24

Reevaluating Radius Health

Radius Health, Inc. has lost over half its value since the transdermal patch version of its approved osteoporosis therapy (TYMLOS) flunked a Phase 3 trial in December 2021. Its other late-stage asset (elacestrant) just passed a Phase 3 study for breast cancer, but revenue from it will be muted since it divested its developmental and commercial rights to. Some recent small wins for subcutaneously injected TYMLOS, a soon-to-be-investigated CBD asset, and recent beneficial owner buying merited a deeper dive. A full investment analysis follows in the paragraphs below.
Articolo di analisi • Feb 23

When Will Radius Health, Inc. (NASDAQ:RDUS) Become Profitable?

We feel now is a pretty good time to analyse Radius Health, Inc.'s ( NASDAQ:RDUS ) business as it appears the company...
Articolo di analisi • Jan 01

How Much Did Radius Health's(NASDAQ:RDUS) Shareholders Earn From Share Price Movements Over The Last Five Years?

It is doubtless a positive to see that the Radius Health, Inc. ( NASDAQ:RDUS ) share price has gained some 58% in the...

Analisi delle retribuzioni degli amministratori delegati

Come è cambiata la remunerazione di G. Martin rispetto agli utili di Radius Health?
DataCompenso totaleStipendioUtili della società
Jun 30 2022n/an/a

-US$69m

Mar 31 2022n/an/a

-US$73m

Dec 31 2021US$3mUS$600k

-US$70m

Sep 30 2021n/an/a

-US$76m

Jun 30 2021n/an/a

-US$60m

Mar 31 2021n/an/a

-US$87m

Dec 31 2020US$12mUS$413k

-US$109m

Compensazione vs Mercato: La retribuzione totale di G. ($USD 3.49M ) è superiore alla media delle aziende di dimensioni simili nel mercato US ($USD 2.59M ).

Compensazione vs guadagni: La retribuzione di G. è stata coerente con le performance aziendali dell'ultimo anno.

AMMINISTRATORE DELEGATO

G. Martin (63 yo)

2.3yrs
Mandato
US$3,493,881
Compensazione

Mr. G. Kelly Martin has been Executive Chairman of Wren Therapeutics Ltd. since 2018. Mr. Martin serves as the Chief Executive Officer, President and Director at Radius Health, Inc. since April 28, 2020.H...

Gruppo dirigente

NomePosizioneMandatoCompensazioneProprietà
G. Martin
CEO, President & Director2.3yrsUS$3.49mNessun dato
Danielle Holtschlag
VP of Sales & Head of U.S. Sales Channelsless than a yearUS$741.78kNessun dato
Chhaya Shah
Senior VP & Chief Business Officer2.2yrsUS$1.22m0.27%
$ 1.3m
Stavros Manolagas
Founder & Member of the Scientific Advisory Boardno dataNessun datoNessun dato
John Potts
Founder & Member of the Scientific Advisory Boardno dataNessun datoNessun dato
Michael Rosenblatt
Founderno dataNessun datoNessun dato
John Katzenellenbogen
Founder & Member of the Scientific Advisory Boardno dataNessun datoNessun dato
Mark Conley
VP, CFOless than a yearNessun datoNessun dato
Peter Schwartzman
Head of Corporate Financeno dataNessun datoNessun dato
Ethan Holdaway
Head of Investor Relationsless than a yearNessun datoNessun dato
Kim Clarke
General Counselless than a yearNessun datoNessun dato
Rohan Lathia
Head of Corporate & Business Developmentless than a yearNessun datoNessun dato
0.8yrs
Durata media
61.5yo
Età media

Gestione esperta: Il team dirigenziale di RDUS non è considerato esperto (durata media 0.8 anni), il che suggerisce un nuovo team.

Membri del Consiglio di amministrazione

NomePosizioneMandatoCompensazioneProprietà
G. Martin
CEO, President & Director2.3yrsUS$3.49mNessun dato
Stavros Manolagas
Founder & Member of the Scientific Advisory Boardno dataNessun datoNessun dato
John Potts
Founder & Member of the Scientific Advisory Boardno dataNessun datoNessun dato
Michael Rosenblatt
Founderno dataNessun datoNessun dato
John Katzenellenbogen
Founder & Member of the Scientific Advisory Boardno dataNessun datoNessun dato
Jean-Pierre Garnier
Independent Director6.7yrsUS$544.81k0.045%
$ 215.1k
Sean Murphy
Independent Director2yrsUS$534.84k0.012%
$ 55.5k
Willard Dere
Independent Director7.8yrsUS$536.69k0.037%
$ 178.7k
Cecil Richard Lyttle
Chairman of Scientific Advisory Board10.5yrsUS$30.00kNessun dato
Owen Hughes
Independent Chairman9.3yrsUS$832.23k0.034%
$ 163.1k
Catherine Friedman
Independent Director7yrsUS$556.41k0.045%
$ 215.1k
Gary Hattersley
Member of Scientific Advisory Board3.8yrsUS$1.94mNessun dato
6.8yrs
Durata media
68.5yo
Età media

Consiglio di amministrazione esperto: I membri del consiglio di amministrazione di RDUS sono considerati esperti (durata media dell'incarico 6.8 anni).

Analisi aziendale e situazione dei dati finanziari

DatiUltimo aggiornamento (ora UTC)
Analisi dell'azienda2022/08/11 01:54
Prezzo dell'azione a fine giornata2022/08/11 00:00
Utili2022/06/30
Utili annuali2021/12/31

Fonti dei dati

I dati utilizzati nella nostra analisi aziendale provengono da S&P Global Market Intelligence LLC. I seguenti dati sono utilizzati nel nostro modello di analisi per generare questo report. I dati sono normalizzati, il che può comportare un ritardo nella disponibilità della fonte.

PacchettoDatiTempisticaEsempio Fonte USA *
Dati finanziari della società10 anni
  • Conto economico
  • Rendiconto finanziario
  • Bilancio
Stime di consenso degli analisti+3 anni
  • Previsioni finanziarie
  • Obiettivi di prezzo degli analisti
Prezzi di mercato30 anni
  • Prezzi delle azioni
  • Dividendi, scissioni e azioni
Proprietà10 anni
  • Top azionisti
  • Insider trading
Gestione10 anni
  • Team di leadership
  • Consiglio di amministrazione
Sviluppi principali10 anni
  • Annunci aziendali

* Esempio per i titoli statunitensi, per i titoli non statunitensi si utilizzano forme e fonti normative equivalenti.

Se non specificato, tutti i dati finanziari si basano su un periodo annuale ma vengono aggiornati trimestralmente. Si tratta dei cosiddetti dati TTM (Trailing Twelve Month) o LTM (Last Twelve Month). Per saperne di più.

Modello di analisi e Snowflake

I dettagli del modello di analisi utilizzato per generare questo report sono disponibili sulla nostra pagina Github; abbiamo anche guide su come utilizzare i nostri report e tutorial su Youtube.

Scoprite il team di livello mondiale che ha progettato e realizzato il modello di analisi Simply Wall St.

Metriche di settore e industriali

Le nostre metriche di settore e di sezione sono calcolate ogni 6 ore da Simply Wall St; i dettagli del nostro processo sono disponibili su Github.

Fonti analitiche

Radius Health, Inc. è coperta da 12 analisti. 6 di questi analisti ha fornito le stime di fatturato o di utile utilizzate come input per il nostro report. Le stime degli analisti vengono aggiornate nel corso della giornata.

AnalistaIstituzione
Gregory HarrisonBofA Global Research
John NewmanCanaccord Genuity
Mara GoldsteinCantor Fitzgerald & Co.